Immunovant reports Q1 FY2025 net loss $87.2M; completes batoclimab MG enrollment

Immunovant, Inc.

2025-Q1 EPS reported -$0.60

Net loss $87.2M ($0.60/share) vs $73.9M ($0.57) YoY; cash $560M as of June 30, 2024.
R&D expenses $75.5M, up 49% YoY, driven by IMVT-1402 prep and batoclimab trials.
Completed enrollment in batoclimab pivotal MG trial; top-line results expected by March 31, 2025.
Plans to initiate 4-5 potentially registrational programs for IMVT-1402 by March 31, 2025; 3 IND applications active by end-2024.
Graves' disease program update expected fall 2024; batoclimab TED top-line data in H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.